The table below shows all shareholders who file Form 13G and all insiders with a 1%+ stake on a fully-diluted basis (based on 49.1M diluted shares: #msg-42163809). Insider holdings include restricted stock and options, whether or not vested. Non-insider holdings other than Novartis are as of 12/31/09 unless otherwise indicated in the table footnotes. (As a 10% owner on an SEC reporting basis, Novartis’ filing requirements are the same as those of insiders.)
Shares Stake Novartis 4,708,679 9.6% T Rowe Price 4,520,273 9.2% BlackRock Inc. 2,782,260 5.7% Visium Asset Mgmt 2,307,096† 4.7% Samana Capital 2,048,303 4.2% Craig Wheeler (CEO) 1,145,469 2.4% G. Venkataraman (SVP, R&D) 631,315 1.3% Ram Sasisekharan (Director) 507,344 1.0%